• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » DermaSensor raises $10M as it braces for U.S. launch

DermaSensor raises $10M as it braces for U.S. launch

June 15, 2022 By Sean Whooley

DermaSensor
[Image from DermaSensor]
DermaSensor announced today that it raised an additional $10 million as it prepares for a commercial launch in the U.S.

Miami, Florida-based DermaSensor’s $10 million fundraising accompanies news that the company met all primary endpoints for two FDA pivotal studies, setting it up to potentially offer the only FDA-cleared, automated skin cancer detection tool on the market that uses any kind of imaging or optical technology.

The DermaSensor device received FDA breakthrough device designation in 2021, and the company expects it to become the first device cleared by the FDA to assist PCPs in evaluating skin cancer.

According to a news release, the device uses a form of optical spectroscopy (called elastic scattering spectroscopy, or ESS) to take non-invasive samples of tissue, capturing cellular-level information from the skin lesion using hundreds of wavelengths of light in a manner similar to how sonar uses sound.

It provides output directly to the user without the need for a laboratory or another physician to analyze the spectral data, with the proprietary algorithm set up to immediately assess the data and provide results in seconds.

The technology could help general practitioners better spot lesions that are potential problems before forwarding their patients to a dermatologist for further evaluation — boosting the ability of the healthcare system to catch skin cancers early.

Last month, the mid-stage company won the MedTech Innovator Mid-Stage Companies Pitch Event, beating out 1,000 applicants, more than 20 of which competed at DeviceTalks Boston. DermaSensor earned a cash prize and admission to MedTech Innovator and its benefits.

DermaSensor said the oversubscribed $10 million financing was led by existing investors, including Ceros Capital Markets. With the newly secured funding, the company is hiring for a range of roles, including chief commercial officer.

“This $10 million in additional capital is a clear vote of confidence, from both existing and new investors, in our strong clinical evidence and in the potential of our product to greatly improve the detection of skin cancer by PCPs,” DermaSensor CEO Cody Simmons said in the release. “This could provide major public health benefits since skin cancer is the most common cancer and there are more primary care physicians than any other specialty.”

Additionally, the company’s Derm-Success FDA pivotal clinical study of more than 1,000 patients across 22 centers around the world, met both of its primary endpoints. DermaSensor’s second pivotal study, which involved more than 100 physicians and showed that the use of the device’s test results improved the detection of skin cancer, met both primary endpoints.

The company also recently published another prospective study (Derm-Assess III) that enrolled more than 500 lesions suspicious for melanoma across 10 dermatology study centers. The study demonstrated DermaSensor’s effectiveness in detecting melanoma while ruling out benign lesions.

“In addition to five other previously completed clinical studies, we have also now successfully completed three of the largest prospective clinical validation and clinical utility studies ever done for regulatory clearance for any kind of skin cancer detection tool,” Simmons said. “And having already complied with regulatory requirements in Europe, Australia and New Zealand, we look forward to working with the FDA through the premarket review process.” 

Filed Under: Business/Financial News, Clinical Trials, Diagnostics, Featured, Food & Drug Administration (FDA), Funding Roundup, Imaging, News Well, Oncology, Regulatory/Compliance Tagged With: dermasensor

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy